Ono Pharmaceutical (OTCMKTS:OPHLF) Announces Quarterly Earnings Results

Ono Pharmaceutical (OTCMKTS:OPHLF) posted its quarterly earnings data on Monday. The company reported $0.40 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $0.29 by $0.11, Zacks reports. The company had revenue of $892.70 million for the quarter, compared to analyst estimates of $727.58 million. Ono Pharmaceutical had a net margin of 12.29% and a return on equity of 7.81%.

Ono Pharmaceutical Price Performance

Shares of Ono Pharmaceutical stock opened at $15.22 on Wednesday. Ono Pharmaceutical has a 1-year low of $9.20 and a 1-year high of $15.22. The company has a market capitalization of $7.15 billion, a PE ratio of 17.10 and a beta of 0.25. The company has a debt-to-equity ratio of 0.11, a current ratio of 2.99 and a quick ratio of 2.50. The business has a 50-day moving average of $13.68 and a 200-day moving average of $12.23.

About Ono Pharmaceutical

Ono Pharmaceutical Co, Ltd., founded in 1717 and headquartered in Osaka, Japan, is a research‐based pharmaceutical company specializing in the discovery, development and marketing of innovative therapies. With origins as a traditional pharmacy, Ono has grown into a global biopharmaceutical entity focused on delivering new treatment options across several therapeutic areas, including oncology, immunology, cardiovascular and antiviral diseases. The company conducts comprehensive research programs spanning early drug discovery through to clinical development.

One of Ono’s most recognized products is the immune checkpoint inhibitor nivolumab, marketed in collaboration with Bristol-Myers Squibb under the trade name Opdivo.